Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu

Journal of Clinical Pathology

Volumn 59, Issue 12, 2006, Pages 1327-1330

  Iczkowski, K A ^a,b   Montironi, R ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUFFER; CITRIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA;

ACINAR CELL CARCINOMA; ADENOID CYSTIC CARCINOMA; ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; CANCER GRADING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG METASTASIS; MALE; PRIORITY JOURNAL; PROSTATE ADENOID CYSTIC BASAL CELL CARCINOMA; PROSTATE CARCINOMA; PROTEIN EXPRESSION; TREATMENT PLANNING;

ADULT; AGED; CARCINOMA, ADENOID CYSTIC; CARCINOMA, BASAL CELL; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; MIXED TUMOR, MALIGNANT; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; RNA, MESSENGER; RNA, NEOPLASM;

EID: 33845983246     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.035147     Document Type: Article

References (12)

1. Iczkowski KA, Ferguson KL, Grier DD, et al. Adenoid cystic/basal cell carcinoma of the prostate: clinicopathologic findings in 19 cases. Am J Surg Pathol 2003;27:1523-9.
2. Karja V, Syrjanen S, Kataja V, et al. c-erbB-2 oncogene expression in salivary gland tumors. ORL J Otorhinolaryngol Relat Spectiose 1994;56:206-12.
3. Lara PN Jr, Meyers FJ, Gray CR, et al. HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer 2002;94:2584-9.
4. Sanchez KM, Sweeney O, Mass R, et al. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a request for a standardized, organ specific methodology. Cancer 2002;95:1650-5.
5. Nagao T, Gaffey TA, Serizawa H, et al. Differentiated adenoid cystic carcinoma: a clinicopathologic study of 6 cases. Mod Pathol 2003;16:1265-72.
6. Montironi R, Mazzucchelli R, Stramazzotti O, et al. Basal cell hyperplasia and basal cell carcinoma of the prostate: a comprehensive review and discussion of a case with c-erbB-2 expression. J Clin Pathol 2005;58:290-6.
7. Iczkowski KA, Bai S, Pantazis CG. Prostate cancer overexpresses CD44 variants 7-9 at the messenger RNA and protein level. Anticancer Res 2003;23:3129-40.
8. McKenney JK, Amin MB, Srigley JR, et al. Basal cell proliferations of the prostate other than usual basal cell hyperplasia: a clinicopathologic study of 23 cases, including four carcinomas, with a proposed classification. Am J Surg Pathol 2004;28:1289-98.
9. Ross JS, Sheehan CE, Hayner-Buchan AM, et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997;79:2162-70.
10. Lin CM, Li AF, Wu LH, et al. Adenoid cystic carcinoma of the trachea and bronchus-a clinicopathologic study with DNA flow cytometric analysis and oncogene expression. Eur J Caradiothoracic Surg 2002;22:621-5.
11. Ariga R, Zarif A, Korasik J, et al. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 2005;11:278-80.
12. Kolar Z, Dvorackova J, Plevovoa P. What is the real importance of evaluating the expression of c-erbB-2 (HER-2/neu) in carcinoma of the breast and prostate? Cesk Patol 2002;38(Suppl 1):15-19.